IDORSIA AG SF-,05
1,97€
+0,13 (+7,08%)
26.04.2024, 22:59:13 Uhr
WKN: A2DTEB ISIN: CH0363463438 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +243,73 +1,36% 18.161,01
- MDAX ® +132,30 +0,51% 26.175,48
- TecDAX ® +55,73 +1,71% 3.322,49
- E-STOXX 50 ® +67,84 +1,37% 5.006,85
- NASDAQ 100 +287,79 +1,65% 17.718,30
- NIKKEI +620,41 +1,64% 38.345,55
- HANG SENG +391,28 +2,26% 17.651,15
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 1,97€ | +7,08% |
| 1 Woche | 2,03€ | -3,22% |
| 1 Monat | 2,51€ | -21,81% |
| 6 Monate | 1,80€ | +9,29% |
| Lfd. Jahr (YTD) | 2,47€ | -20,42% |
| 1 Jahr | 9,18€ | -78,59% |
| 3 Jahre | 24,37€ | -91,93% |
| 5 Jahre | 17,99€ | -89,07% |
Kursdaten
| Kurs | 1,97€ |
| Eröffnung | 1,85€ |
| Geld | 1,91€ |
| Brief | 1,98€ |
| Tages-Hoch | 1,97€ |
| Tages-Tief | 1,81€ |
| 52 Wochen-Hoch | 9,65€ |
| 52 Wochen-Tief | 1,37€ |
| Allzeit-Hoch | 31,65€ |
| Allzeit-Tief | 1,37€ |
Nachrichten
- GlobeNewswire: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension - 26.04.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia publishes an invitation to a bondholder meeting - 23.04.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia publishes a Financial Status required for an upcoming bondholder meeting - 17.04.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia takes steps to address short-term liquidity needs - 11.04.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia thanks Guy Braunstein for his years of service as he retires - 22.03.2024, 07:00:00 Uhr
- GlobeNewswire: US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives - 20.03.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia and Viatris successfully close the transaction for the global research and development collaboration - 18.03.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia and Viatris enter into a significant global research and development collaboration - 28.02.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation - 10.01.2024, 07:00:00 Uhr
- GlobeNewswire: New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 - 03.11.2023, 22:30:00 Uhr
